INKT MiNK Therapeutics, Inc.

Nasdaq minktherapeutics.com


$ 12.75 $ -0.25 (-1.92 %)    

Friday, 14-Nov-2025 10:17:46 EST
QQQ $ 611.08 $ 11.52 (1.92 %)
DIA $ 473.04 $ 1.62 (0.34 %)
SPY $ 673.93 $ 8.48 (1.27 %)
TLT $ 88.97 $ -0.82 (-0.91 %)
GLD $ 376.54 $ 3.69 (0.99 %)
$ 13.22
$ 12.72
$ 12.78 x 1
$ 13.03 x 3
$ 12.71 - $ 12.75
$ 4.56 - $ 76.00
18,917
na
59.79M
$ 2.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-29-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mink-therapeutics-q3-eps-065-misses-061-estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $...

 mink-therapeutics-files-for-mixed-shelf-offering-up-to-150m

-SEC Filing

 mink-therapeutics-presents-updated-clinical-results-evaluating-agent-797-alone-and-in-combination-with-anti-pd-1-therapy-in-patients-with-advanced-solid-tumors-refractory-to-all-approved-treatments-at-sitc-2025

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months...

 mink-therapeutics-announces-that-late-breaking-phase-1-data-for-its-allogeneic-inkt-cell-therapy-agent-797-will-be-presented-at-40th-annual-sitc-meeting-nov-79-2025

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

 hc-wainwright--co-upgrades-mink-therapeutics-to-buy-maintains-price-target-to-35

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the ...

 mink-therapeutics-q2-eps-106-misses-046-estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $...

 hc-wainwright--co-downgrades-mink-therapeutics-to-neutral-maintains-price-target-to-35

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains th...

 mink-therapeutics-highlights-inkt-cell-therapy-potential-in-peer-reviewed-article-titled-car-inkt-cells-redefining-the-frontiers-of-cellular-immunotherapy-underscoring-the-power-of-car-inkt-as-next-gen-solid-tumor-treatment

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

 william-blair-downgrades-mink-therapeutics-to-market-perform

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION